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Abstract: Immunotherapy has provided a new avenue to
treat metastatic cancers, which result in ∼90% of cancer
related deaths. However, current immunotherapies, such
as immune checkpoint therapy (ICT), havemetwith limited
success, primarily due to tumor intrinsic and extrinsic
factors that inhibit antitumor immune responses. To
overcome the immune suppression of the tumor microen-
vironment (TME) and enhance the tumoricidal activity of
ICT, phototherapy, particularly photothermal therapy
(PTT), combined with nanomedicine has become a viable
option. PTT disrupts target tumor homeostasis, releasing
tumor associated antigens (TAAs), tumor specific antigens
(TSAs), danger associated molecular patterns (DAMPs),
and scarce nutrients required to “feed” activated antitumor
immune cells. While nanoparticles localize and specify
the phototherapeutic effect, they can also be loaded with
immune stimulants, TME modulators, and/or chemother-
apeutic agents to greatly enhance immune stimulation and
tumor killing. Combining these three technologies, which
we term nano-ablative immunotherapy (NAIT), with ICT
can greatly enhance their therapeutic effects. In this
review, we will discuss the successes and limitations of
NAIT+ ICT. Specifically, wewill discuss how the TME limits
tumoricidal activity and what should be considered to
overcome these limitations.
Keywords: photonics; nanomedicine; cancer immuno-
therpay; immune checkpoint therapy; nano-ablative
immunotherapy; tumor microenvironment.
1 Introduction
Nanoparticles, photonics, immunology, and immuno-
therapy are seemingly modern terminologies, yet the
science and applications of these technologies have been
with us for thousands of years. From colorful paintings on
ancient church windows to other glasses and metallic
devices, metal nanoparticles have been used to bring
technological ideas into our daily life. However, only
recently have these nanoparticles been incorporated in
to medicine and emerged as a new field of study,
nanomedicine.
For the human body, light is both beneficial and
harmful. Too much exposure can result in DNA damage,
premature aging, and skin cancer formation [1–4].
Conversely, light can prevent vitamin D deficiency, pro-
mote wound healing, and treat/cure cutaneous infections
and other skin conditions [4–7]. With the advent of lasers,
light has emerged as a useful medical tool for harnessing
the biomedical effects of photothermal, photomechanical,
and photochemical interactions to treat specific conditions
including cancer.
Immunotherapy has become a major branch of mod-
ern medicine and cancer therapy [8–11]. Exploiting the
immune system to attack cancer cells is highly favorable
because immune cells travel throughout the body,
providing constant immune surveillance, and help prevent
relapse [11–13]. Unfortunately, not all tumors are created
equal, and most do not respond to current immunother-
apies for a variety of reasons [9, 14–16].
Combining different technologies has time and again
produced new, exciting innovations to overcome current
technological and medicinal limitations. Synergizing
nanomedicine with phototherapy and immunotherapy is
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a viable option to overcome the current limitations of
cancer therapeutics and has been the subject of several
recent reviews [17–21]. In this review, we will discuss the
types of tumor microenvironment (TME) that lead to
failure of immune checkpoint therapy (ICT) in human
patients, and the competing “arms race” that continually
evolves between cancer and the immune system. This will
provide a unique angle to review the current research in
this field and to lay the foundation for designing cancer
therapeutic approaches combining nano-, photo-, and
immuno-treatments. Furthermore, we specifically high-
light preclinical and clinical studies that employed com-
pound nanoparticles that successfully combined all three
approaches, which we term nano-ablative immuno-
therapy (NAIT).We also highlight the fact that NAIT could
turn ICT resistant tumors into responders. Lastly, we will
discuss the current limitations of NAIT + ICT due to tumor
intrinsic and extrinsic factors and provide guidance
for incorporating TME modulators with NAIT + ICT to
potentially surmount these obstacles to enhance absco-
pal effect and promote long-term cancer control, to
effectively treat metastatic cancers and to prevent cancer
recurrence.
2 Cancer immunology and cancer
immunotherapy
With the complexity of life, the immune system has
evolved ways to monitor “self” cells and remove “altered”
or “non-self” cells to prevent abnormal cell growth and
promote organismal survival. The key immune cells
involved in this process are natural killer (NK) cells and
CD4+ and CD8+ T cells [22–24]. Cancer arises when these
cells fail to eliminate and/or control abnormal cell growth.
At some point in cancer development, an equilibrium is
reached in which the immune system inadvertently selects
and tolerates tumor cells better capable of evading im-
mune attack, and then these tumor cells establish a TME
that further alludes antitumor immune responses and
promotes unimpeded growth. This process of cancer
development was coined “cancer immunoediting” by
Dunn and Schreiber [25] in that the TME co-evolves in
response to its interactions with its surrounding tissues
and immune cells. This hypothesis is given further
credence by the fact that essentially all solid tumors are
infiltrated with a diverse array of myeloid and lymphoid
leukocytes [26]. Importantly, the level of immune infiltra-
tion, activation, and composition are dependent on cancer
type and malignancy stage [27]. Moreover, the type of
infiltrating immune cells correlates with prognosis of pa-
tients with similar cancer types. For example, patients with
large numbers of immature myeloid cells, tumor associ-
ated macrophages (TAMs), plasmacytoid dendritic cells
(pDCs), and/or neutrophils are associated with treatment
resistance and poor prognosis [28–33]. In contrast, cancer
patients with high concentrations of CD8+ andmemory Th1
CD4+ T cells, B cells, and NK cells in the TME have signif-
icantly greater disease-free survival (DFS) and overall
survival (OS) following various cancer treatments [33–38].
To unleash the antitumor capability of the tumor infil-
trating T cells, cancer immunotherapy holds high promise
to treat cancer through immunological means.
Several immunotherapies have been used to treat
cancer patients, such as bacterial or viral inoculation,
cytokine infusion, cancer vaccines, and CAR-T therapies
[39–41]. Unfortunately, each of these therapies is limited to
enhancing the existing immune response or identifying
tumor specific antigens (TSAs) for efficient vaccination. To
overcome these limitations, other targets are currently
being pursued to specifically target the immune suppres-
sive cytokines, metabolites, and immune suppressive cells
within the TME [42–46].
Among the immunotherapies, ICT is the most used
immunotherapy to date. While it also relies on the existing
immune response, it has shown increased efficacy when
combined with other therapies [47–50], and such combi-
nations will be the focus of this section. The most used ICT
to date targets the immune inhibiting ligands CTLA-4 and
PD-1 on the surface of T cells via blocking antibodies.While
there are several other inhibiting ligands [51, 52], we will
focus on these two ligands in this review. CTLA-4 and PD-1
are expressed on activated T cells and under normal con-
ditions are required to maintain immune homeostasis and
prevent the development of autoimmunity [53]. However,
in cancer, these molecules are highly expressed in the TME
and severely dampen antitumor immune responses and
prevent tumor killing. Unfortunately, across a broad range
of cancers, the response rate to ICT is only ∼10–20%, far
below an acceptable rate [15]. There are several factors
contributing to this failure, and clinically patients are
grouped into three categories based on their failure to
respond to ICT: Primary Resistance, Adaptive Resistance,
and Acquired Resistance (Figure 1) [54–57]. Primary re-
sisters do not have a response to ICT, and it is hypothesized
that a lack of sufficient T cell responses, tumor mutational
burden, tumor peptide presentation on the tumor surface,
and/or an unfavorable TME actively prevents sufficient
immune responses. Adaptive immune resisters are thought
to have sufficient antitumor T cell responses, but the
TME prevents sufficient tumor killing through a variety of
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mechanisms. There are also patients who initially respond
to ICT but then relapse and the cancer progresses, resul-
ting in acquired resistance. Based on these clinical pre-
sentations, the immune system and the TME are enemies at
war. The immune system is trying to attack and control
tumor growth while the TME is continually evolving to find
an avenue to stymie immune attack via tumor intrinsic or
extrinsic factors.
Each TME is unique as it is actively shaped by its
surrounding tissue environment and immune responses as
it evolves [58]. It is for this reason that a one-size-fits-all
cancer approach has had little success. Despite these dif-
ferences, there are several key hallmarks of solid TMEs
which favor tumor progression and inhibit antitumor
immune functions. This includes hypoxia, amino acid,
glucose, glutamine, and lipidmetabolism, lactate buildup,
reactive oxygen species (ROS) dependence, acidification
due to hypoxia and lactate accumulation, dysregulated
angiogenesis, and high interstitial fluid pressure (IFP)
[59–65]. These hallmark signatures are generated through
coordinated interactions between tumor cells, immune
cells, and stromal cells at the behest of the tumor cells.
Hypoxia is a characteristic of∼50%of solid tumors and
plays a critical role in driving tumor progression and
shaping the antitumor immune response through a variety
of pathways (Figure 2) [65–68]. In tumors, hypoxia is one
of the strongest angiogenesis signals driving blood ves-
sel formation to “feed” the growing tumor. Hypoxia also
upregulates the glucose uptake machinery, to compensate
for the inefficiency of glycolysis for energy production,
while simultaneously inhibiting mitochondrial respiration
[69]. By exclusively using glycolysis, lactate accumulates
and drives acidification of the TME. Additionally, hypoxia
induces tumor cells to secrete anti-inflammatory cyto-
kines TGF-β, IL-10, and chemokine ligands (CCLs), which
recruit immunosuppressive cells such as tumor associated
Figure 1: Resistance against immune checkpoint therapy.
(A) Patient’s tumor is resistant to immunotherapy with no active immune response. (B) Patient’s tumor is resistant to immunotherapy with
active anti-tumor immune responsebut turned off by checkpoints or other adaptive resistancemechanisms. (C) Patient has an initial response
to immunotherapy but later progressed; heterogeneous population and selection of resistant clones were present before treatment started.
(D) Patient has an initial response to immunotherapy but later progressed, a true acquired resistance during the immunotherapy. Reprinted
with permission from reference [54]. Figure obtained from https://doi.org/10.1016/j.cell.2017.01.017.
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macrophages (TAMs), tumor associated neutrophils
(TANs), and myeloid derived suppressor cells (MDSCs),
which further promote tumor growth and immune repres-
sion (Figure 2) [70–72]. TGF-β plays a critical role in
increasing the IFP as it transforms fibroblasts into cancer-
associated fibroblasts (CAF) and induces collagen deposi-
tion [64, 73–75]. CAFs contribute to tumor growth and
metastases by releasing extracellular matrix (ECM) pro-
teins that promote survival, inhibit immune activation,
promote oxidative phosphorylation, and drive epithelial to
mesenchymal transition (EMT), as shown in Figure 2 [76].
TAMs are the largest portion of myeloid cells residing
in solid tumors [77]. With the use of animal studies, it is
suggested that a majority of the TAMs residing in the TME
originates asmonocytes that are recruited into the TME, via
cytokines and chemokines [78, 79], where they encounter
an immune suppressive environment [80–82]. Monocytes
that differentiate intomacrophages are incredibly dynamic
and diverse, and they adapt to their microenvironment
based on the environmental cues they receive [83, 84]. In
an established TME,monocyteswill encounter factors such
as hypoxia, low pH, metabolic and environmental stress
signals, and anti-inflammatory cytokines, such as IL-4,
IL-10, and TGF-β, all of which drive the differentiation of
monocytes into macrophages with pro-tumor, immune
inhibiting functions [78, 79, 85–87]. With tumor progres-
sion, TAMs display a more pro-tumor phenotype, and can
produce an abundance of immune-modulatory chemo-
kines and cytokines that prevent efficient immune medi-
ated tumor killing (Figure 2). Additionally, TAMs can
directly interact with T cells to physically prevent them
from associating with tumor cells. To the benefit of the
tumor, these TAMs also secrete several molecules that
contribute to tumor angiogenesis, inhibit tumor apoptosis,
and promote metastasis [84]. For this reason, large
numbers of TAMs with these properties residing within the
TME lead to treatment resistance and poor patient prog-
nosis [84, 88, 89].
Figure 2: The interconnected web of the tumor microenvironment (TME). In the TME, tumor cells and immune cells are in constant
communication. The TME is acidic, nutrient deficient, and hypoxic, which promotes an immunosuppressive environment. Additionally, the
tumor cells and cancer associated fibroblasts (CAFs) secrete factors that promote tumor growth, inhibit immune cell activation, and recruit
immunosuppressive immune cells. The immunosuppressive cells, such as M2-like macrophages (M2-like TAMs), myeloid derived suppressor
cells (MDSCs), T regulatory cells (Treg), and tumor associated neutrophils (TANs), not only suppress antitumor immunity directly (via
expression of inhibitory receptors) or indirectly (cytokines, chemokines, etc.), but also promote tumor growth andmetastasis through various
mechanisms such as inhibiting dendritic cell (DC), natural killer (NK) cells, and cytotoxic T cell (CTL) functions.
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Like TAMs, MDSCs have a dual functionality in pro-
moting tumor progression and inhibiting antitumor im-
munity (Figure 2) [90, 91]. MDSCs secrete several growth
factors and matrix metalloproteases that promote tumor
angiogenesis, growth, and metastases [92, 93]. While
MDSCs have global tumor promoting and immunosup-
pressive functions, their primary targets are T cells through
the production of arginase-1, iNOS, TGF-β, IL-10, COX2,
indoleamine 2,3-dioxygenase (IDO), sequestration of
cysteine, etc. [90, 91, 94]. More importantly, MDSCs are
capable of driving antigen specific Treg formation, effec-
tively tolerizing T cells to the tumor, hence preventing
tumor killing [90]. Tregs are highly suppressive T cells
capable of inhibiting cytotoxic T cell (CTL) function either
directly or indirectly through killing the cells, induction of
checkpoint signaling, anti-inflammatory cytokines,
sequestration of IL-2, inhibition of dendritic cell function,
and/or metabolic modulation of adenosine and trypto-
phan (Figure 2) [95–97]. Due to their various abilities to
suppress CTL responses, high infiltration of Tregs into tu-
mors is associated with poor prognosis [98–100].
As briefly described above, the TME generates a
localized ecosystem composed of many inter-connected
players that contribute to cancer survival. For this reason,
removing and/or activating one key player will likely have
little effect as many of the other players can easily fill the
void, allowing the tumor to evolve and overcome the
treatment regimen (Figure 2). This is reflected in the fact
that cancers develop resistance and require alternative
treatment therapies. Furthermore, late-stage tumors are
more resistant to current cancer treatments, with single
treatments having little benefit [101, 102]. Thus, a multi-
modal therapeutic strategy is required to surmount the
resistance mechanisms and plasticity inherent to well
established tumors. In the following sections, we will
describe how photo-ablative therapy combined with
nanomedicine can address and overcome some of these




Photodynamic therapy (PDT) is a minimally invasive,
well established treatment modality that drives the
production of ROS to induce cellular toxicity and
apoptosis [103–106]. PDT combines non-ionizing light at
a wavelength of 400–700 nm [107], a photosensitizer
(PS), and oxygen [108, 109]. PS are generally aromatic
molecules that absorb light at specific wavelengths and
generate ROS in the presence of oxygen and light [110].
ROS results in tissue damage and immunogenic cell
death (ICD) that is capable of stimulating an immune
response [108]. Specifically, the PDT-induced ICD re-
leases danger associated molecular patterns (DAMPs),
leading to CD8+ T cell proliferation, cytotoxic cyto-
kine secretion, and other immune responses, which can
trigger or potentiate antitumor immunity [111–113]. Un-
fortunately, in hypoxic TMEs, PDT is severely hindered
due to lack of oxygen, which is required to generate
ROS [114], and PS are generally hydrophobic which
limits their solubility and ability to enter target tissues
[115–119]. Furthermore, PDT-induced immune responses
cannot achieve satisfactory therapeutic effects alone,
particularly against metastatic tumors. Another limita-
tion of PDT is the tissue penetration of light [120]. To
overcome these limitations PDT is being combined with
nanotechnology to improve PS delivery to target tissues,
overcome hypoxic TMEs [114, 121–125], and enhance the
light absorption for deep-seated tumors. The use of
nanoparticles and PDT for cancer therapy has been
extensively reviewed elsewhere [116–119, 122, 125–127].
3.2 Photothermal therapy
Photothermal therapy (PTT) is a treatment modality that
commonly employs near-infrared (NIR) light energy and
locally placed light-absorbing agents to generate heat and
destroy cancer cells. PTT is minimally invasive and can be
used topically or interstitially for tumor treatment with
minimal toxicity to surrounding tissues. Temperature
elevation has a direct impact on the tissue biological re-
sponses. Above 100 °C, tissue experiences carbonization
and evaporation, which have minimum contribution to
immune responses. Cytotoxic temperature (46–100 °C)
usually leads to cell death and release of antigens and
DAMPs. Below the cytotoxic temperature, cells are under
thermal distress, but usually remain viable. Even though
each tumor and its TME are unique, there is a consensus
that effective PTT requires a sustained tumor temperature
of ∼50–60 °C [128–131] for optimal tumor cell killing and
immune stimulation via ICD. This is largely due to the type
of cell death that is required to stimulate an immune
response.
To date, three main types of programmed cell death
have been described, apoptosis, pyroptosis, and nec-
roptosis [132, 133]. Apoptosis is largely an anti-inflammatory
form of cell death that does not release cellular antigens or
DAMPs capable of stimulating immune responses [134].
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Necrosis, in contrast to necroptosis, is an uncontrolled form
of ICD, in which cellular contents and DAMPs are released
into the cytosol from rupturing cells [135, 136]. Therefore,
the goal of PTT should be to initiate ICD to release tumor
associated antigens (TAAs), TSAs, and DAMPs to stimulate
antitumor immunity, and disrupt overall tumor homeosta-
sis to allow for immune infiltration and tumor killing
[128–131, 137, 138].
To protect the surrounding healthy tissue, combining
PTT with nanoparticles is desirable. Nanoparticles make it
possible to specifically increase target tumor temperature
at much lower power densities, resulting in negligible
temperature changes in the surrounding nanoparticle-free
tissues [139, 140]. Several nanoparticles with varying heat
generating mechanisms and morphologies have been
developed [141]. These include rare earth ion nanocrystals,
carbon nanoparticles, metallic nanoparticles, organic
nanoparticles, and organic biodegradable nanoparticles,
which have been extensively reviewed elsewhere
[140–144].
Due to the immunosuppressive nature of the TME, the
release of DAMPs, TSAs, and TAAs, as well as disruption of
tumor homeostasis by PTT alone are not sufficient to
stimulate satisfactory systemic antitumor immunity. We
will highlight a few approaches that have combined nano-
mediated PTT with immune stimulating agents, which we
will refer to as NAIT. Furthermore, we would like to
emphasize that stimulating immunity alone may not be
enough and that combining NAIT with TME modulating
molecules may be required to further improve the systemic
effects to treat a broad range of metastatic cancers.
4 Nano-ablative immunotherapy
In the United States, ∼44% of cancer patients are eligible
for ICT, but only 13% of these patients are estimated to
respond favorably [15]. There are many factors that
contribute to low response rates, and clinically patients
who resist ICT are grouped into three categories, as listed
above, due to tumor intrinsic and extrinsic factors. To
overcome the TME obstacles and allow for better responses
to ICT, NAIT is becoming a viable option. PTT disrupts
target tumor homeostasis and releases TAA, TSA, and
DAMPs, allowing for the influx of immune cells. The
nanoparticles used to enhance the photo-ablative effect
can also be used to deliver immune stimulating molecules
and chemotherapeutic drugs capable of enhancing exist-
ing immune responses and possibly driving de novo anti-
tumor T cell responses. Through its T cell activation, NAIT
has great potential to synergize with ICT to enhance tumor
killing. In the following sections, evidence from clinical
and preclinical models illustrating this effect will be
presented.
4.1 Clinical case reports
In a case report, Chen and colleagues treated a stage IV
aggressive metastatic melanoma patient with a combina-
tion of PTT, immune stimulation via imiquimod, and ipi-
limumab (anti-CTLA-4) ICT [145]. This patient had failed
other traditional treatment modalities and had epidermal
metastases on the neck and head and deep metastases in
the lungs. The cutaneous lesionswere treatedwith PTT and
topical imiquimod for three courses. Threemonths after the
final course, the cutaneous recurrences were completely
cleared, but the lung metastases remained so the patients
began anti-CTLA-4 ICT. Within 9 months, the lung metas-
tases were cleared (Figure 3), and the patient remained
tumor free at the time of this report, 7 years after the
treatment.
For a clinical pilot study, Halas and colleagues used
AuroShells (gold-silica nanoshells) and laser to specifically
ablate prostate tumors for patients in stage IIa or below
[146]. Within 3 months, 10/16 patients were tumor free
while at 12 months 14/16 were tumor free in the ablated
region. The nanoparticles were well tolerated with little to
no side effects reported, giving further credence to the use
of nanoparticles with phototherapy for cancer treatment.
4.2 Experimental NAIT
While very few clinical studies have been performed using
nano-based ablation and immune stimulation, several
preclinical studies have been performed with varying de-
grees of success. In this section, we will specifically high-
light studies that generated multifunctional nanoparticles,
which combined immune stimulants into the nanoparticle,
to increase the efficacy of PTT and/or their ability to syn-
ergize with ICT.
Using a photothermally activated polymeric nano-
agonist (APNA), Pu and colleagues generated an NP to
specifically target deep seeded tumors via PTT. APNA
consists of a semiconducting polymer backbone, which
absorbs NIR-II light and is conjugated to the immune
stimulant resiquimod (R848), via a thermolabile linker.
Upon PTT, R848 is cleaved and able to stimulate tumor-
infiltrating DCs and promote TAA and TSA uptake. This
leads to significantly delayed 4T1 tumor growth and higher
overall survival in the PTT + APNA treated animals [147].
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Similarly, using manganese ferrite (MnFe2O4), generated
from iron oxide and manganese oxide, Chen and col-
leagues developed a compound NP containing R837, a
TLR-7 agonist, and coated with ovalbumin. The MnFe2O4
NPs alone were able to stimulate bone marrow derived
dendritic cells (BMDCs), enhanced by the addition of R837
[148]. In vivo, this combinatorial NP, when combined with
PTT, reduced tumor cell growth and lung metastases,
prolonging the survival of 4T1 inoculated mice. These ex-
periments demonstrate that combining immune stimula-
tion with PTT enhances antitumor immunity presumably
through T cell activation, but these therapies were not
combined with ICT to assess synergy.
Combining upconversion nanoparticles with indoc-
yanine green (ICG), rose bengal (RB), and a lipid mole-
cule (DSPE-PEG-maleimide, mal) as an antigen capturing
agent, Chen and colleagues generated an NIR-triggered
antigen capturing nanoplatform [149]. UCNP/ICG/RB-mal
was able to directly stimulate BMDCs in vitro, suggesting
that this type of NP could not only capture antigen but also
enhance DC activation upon antigen delivery. Using the
4T1 orthotopic breast tumor model, PTT combined with
UCNP/ICG/RB-mal resulted in ∼70% long-term animal
survival. Combining PTT with the NP and anti-CTLA-4 ICT
further improved survival to ∼80%. Most interestingly,
upon 4T1 rechallenge of the cured survivors, only some of
the anti-CTLA-4 ICT receiving mice were capable of
completely preventing tumor growth. This demonstrates
that despite successful tumor elimination upon treatment,
other components, in particular the checkpoint inhibition,
are required to generate long-term antitumor immune
memory.
Fe3O4 nanoparticles have been widely used in cancer
diagnosis and are deemed safe for clinical use. However,
their molar extinction coefficient (MEC) is low, making the
unmodified version unsuitable for PTT applications. Yang
and colleagues generated Fe3O4 superparticles (SP) by
using Fe3O4 as the core and polydopamine (Fe3O4@PDA)
as the shell to greatly increase their MEC, biocompatibility,
and physiological stability [150]. They further combined
this SP with poly(ethylene glycol)-block-poly(lactic-co-
glycolic acid) copolymer (mPEG-PGLA) and R837 to
generate a nanodrug carrier that localizes within the TME
via magnetic attraction and releases R837 upon PTT. 4T1
breast tumors respond very well to Fe3O4-R837 SP, with the
PTT treated tumors regressing significantly after treatment.
However, the abscopal response had little effect until it was
combined with anti-PD-1 ICT [151]. Fe3O4-R837 SP in com-
bination with anti-PD-1 effectively impeded untreated tu-
mor growth for up to 24 days but was unable to eliminate
the tumor. This response highlights the fact that immune
stimulation alone is not sufficient in eliminating “cold”
tumors, which are characterized by poor immune
infiltration.
Similarly, Wong and colleagues developed FePSe3
chitosan coated nanoparticles conjugated with the anti-
PD-1 peptide (APP) to block PD-1/PD-L1 signaling. It was
further coated with cancer cell membrane (CCM) from
Figure 3: CT images of lung metastases of a patient treated with PTT and topical imiquimod for three courses, followed by anti-CTLA-4
(ipilimumab) ICT, showing the same level in the thorax.
(A) The image was taken before ipilimumab treatment (2 months following LIT) and demonstrates the size and location of the pulmonary
metastases (yellow arrow). (B, C) The image shows shrinkage of the pulmonarymetastases 3months (B) and 6months (C) after completion of
the combination of LIT and ipilimumab. (D) The image shows that pulmonarymetastases were completely resolved 9months after completion
of the combination of LIT and ipilimumab. Reprinted with permission from reference [145]. Figure obtained from doi:10.1002/jbio.201600271.
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CT26, the tumor being treated, to camouflage the NP from
the immune system and allow trafficking to the targeted
tumor [152]. The NP generated in this study could modestly
activate dendritic cells (DCs) and induce the production of
IL-12 and IFNγ. Following PTT, FePSe3@APP@CCM NP
was able to significantly control CT26 tumor growth and
prolong survival in ∼50% of the animals. Memory and
abscopal responses were not measured in this study. It
would be interesting to learn if the therapeutic effect of this
NP could be enhanced by the addition of a strong immune
stimulant.
Single-walled carbon nanotubes (SWNTs) are toxic at
high concentrations, but they do result in tumor shrinkage.
If locally administered, they can selectively enhance the
photoabsorbance within the targeted tumor. Chen and
colleagues generated SWNTs coated with a novel immune
stimulant, glycated chitosan (GC), to enhance the anti-
tumor immune response following PTT [153]. Using the 4T1
tumor model, this combinatorial NP was able to extend
survival and reduce tumor metastases in the lungs. 4T1
tumors are refractory to anti-CTLA-4 ICT. However, when
anti-CTLA-4 ICT was combined with PTT and GC-SWNTs,
the efficacy was greatly enhanced resulting in long-term
survival of ∼50% of the treated animals. This study high-
lights the fact that PTT + immune stimulation canmake ICT
resistant tumors responsive, supporting the hypothesis
that NAIT synergizes with ICT.
4.3 NAIT combined with TME modulators
In all the examples detailed above, immune stimulating
NP + PTT therapy was able to control treated tumor growth
and untreated metastasis, but abscopal effects and the
formation of immunememory varied greatly. Additionally,
the treatments were rarely 100% effective even with the
addition of ICT, likely due to heterogeneity of the TME, and
varied immune activation responses among individual
animals.
To expand on this hypothesis, Hou and colleagues
developed a nanocomposite drug delivery system
composed of MXene Ti3C2 to treat MDA-MB-231 xenographs
in nude mice. The Ti3C2 was etched, intercalated, and
delaminated to form sheets, in which metformin (Met) and
compound polysaccharide (CP) were added through layer-
by-layer adsorption [154]. The resulting nanoparticle
(Ti3C2@Met@CP) was able to target the tumor via a three-
pronged approach. First was the disruption of tumor
homeostasis via PTT. Second was the activation of the
innate immune system through CP, which is a composite
of three immune stimulating polysaccharides: lentinan,
pachymaran, and tremella. Last is the metformin, which
activates AMPK via p53, which in turn ceases cell cycle
progression and leads to autophagy and cell death [155].
Thus, any tumor cells not undergoing ICD because of
thermal ablationwere further eliminated through chemical
means either directly or indirectly via the enhanced
infiltration and activation of antitumor immune cells
(Figure 4). While these experiments were done in nude
mice, which have NK cells but lack T cells, this approach
shows promise. Future experiments in immune competent
mice are required to ascertain whether this therapy can
effectively generate long-term antitumor immunity and
prevents tumor growth upon rechallenge.
Using a poly(lactic-co-glycolic) acid (PLGA) nano-
particle shell, Liu and colleagues generated nanoparticles
containing R837 and water-soluble catalase to break
down tumor generated H2O2 into O2 [156].When combined
with radiotherapy, this combinatory therapy dramatically
reduced and/or eliminated tumor growth and prevented
tumor growth upon rechallenged with CT26 tumors
(Figure 5). While this combination therapy used radio-
therapy as the form of ablation, it further expands on the
idea that NAIT + TME modulators are a viable means to
overcome a highly dynamic TME and generate effective
anti-tumor immune memory.
A good example to date of a multimodal therapeutic
approach to the generation of a robust antitumor immune
memory comes from Chen and colleagues (Figure 6). They
generated a multimodal NP from reduced graphene oxide
(rGO), loadedwithmitoxantrone (MTX) and SB-431542 (SB)
[157]. rGO is a dual nanoparticle in that it absorbs NIR light,
but also stimulates the production of proinflammatory
cytokines, such as TNFα, IL-6, and IL1β [158]. MTX func-
tions by disrupting DNA synthesis and repair [159], while
SB prevents TGF-β responses by binding to TGF-β receptors
ALK5, ALK4, and ALK7 [160]. This combination worked
well in treating 4T1 breast tumors, as 70%of the PTT+ rGO/
MTX/SB treated animals went on to clear the tumors.
Furthermore, when the PTT + rGO/MTX/SB cured survivors
were rechallenged with 4T1 tumors, 100% of the initially
cured animals rejected tumors, demonstrating that this
four-tier approach successfully generated a robust anti-
tumor immunememory response. Tomeasure the abscopal
affect, a bilateral 4T1 tumor model was employed, and
T cell infiltration and tumor regression was measured on
the untreated tumors. These experiments revealed that
rGO + PTT could significantly increase the percentage of
tumor-infiltrating CD8+ T cells within the untreated tumor
and is slightly enhancedwith the addition ofMTXandSB to
the rGO. Twenty days after treatment, the PTT + rGO/MTX/
SB treated animals were able to control the growth of the
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untreated tumors, while PTT + rGO and PTT + rGO/MTX
treated animals did not. This is an important finding, as it
further supports the notion that tumor ICD and immune
stimulation are not enough. It reveals that TMEmodulators
are required for immune control of untreated tumors. The
other important finding is that PTT + rGO/MTX/SB treated
animals were able to control the growth of the untreated
tumor but not eliminate it. This suggests that other factors
Figure 4: Nanocomposite drug delivery system composed of MXene Ti3C2 for treatment of MDA-MB-231 xenographs in nude mice.
(A) Schematic of the synthetic process of the (AlOH)4-functionalized Ti3C2 nanosheets by two-step exfoliation, including a ball-and-stick
model (top) and layermodel (below). (B) Schematic of drug loading of Ti3C2 nanosheets, their further surfacemodification by CP, drug release,
and CP degradation. (C) Schematic of the synergetic therapy effect of PTT, PDT and chemotherapy based on Ti3C2 nanosheets. (D) Time-
dependent tumor growth curves after the different treatments. Reprinted with permission from reference [154]. Figure obtained from https://
doi.org/10.1039/D0TB01084G.
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Figure 5: A poly(lactic-co-glycolic) acid (PLGA) nanoparticle shell, combined with radiotherapy, for treatment of CT26 tumors.
(A) The schematic illustration formechanism of antitumor immune responses induced by PLGA‐R837@Cat‐based radiotherapy in combination
with checkpoint‐blockade to inhibit cancermetastases and recurrence. (B)Modulation of tumormicroenvironment after intratumoral injection
of PLGA‐R837@Cat. Representative immunofluorescence images of tumor slices after hypoxia staining. The hypoxia areas and blood vessels
were stained by anti-pimonidazole antibody (green) and anti‐CD31 antibody (red), respectively. (C) The relative hypoxia positive areas and
blood vessel densities as recorded from more than 10 images for each sample using the ImageJ software. (D) Schematic illustration of PLGA‐
R837@Cat‐based radiotherapy (abbreviated at RT) and αCTLA4 combination therapy to inhibit cancer relapse. (E) Tumor growth curves of
rechallenged tumors inoculated 40 days post elimination of their first tumors (eight mice per group) by surgery or RT plus αCTLA4. Reprinted
with permission from reference [156]. Figure obtained from https://doi.org/10.1002/adma.201802228.
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are required such as another dose of the three-tier NP, or
another TME modulator to disrupt the immunosupp-
ressive function of the established TME for complete
immune-mediated tumor removal. Furthermore, the
type of immune stimulant used to enhance antitumor
immunity needs to be carefully considered. Type I IFNs
are critical for antitumor immune responses and con-
trolling tumor growth [161–163]. Combining this type of
multimodal NPs with a strong type I IFN stimulant may
lead to greater abscopal effects and tumor elimination.
The pre-clinical and clinical studies described above
are summarized in Table 1.
B C
Figure 6: Reducedgrapheneoxide (rGO), loadedwithmitoxantrone (MTX) andSB-431542 (SB), formultimodal therapy treatment of 4T1 tumor.
(A)Schematic of laser + rGO/MTX/SB treatment of 4T1 tumors inmice and themechanismof induced antitumor immune response. (B)Survival
rates of tumor-bearingmice in the indicated treatment groups (with laser irradiation) up to 100 days after the initial tumor inoculation. (n= 10,
*p < 0.001 vs. Laser; #p < 0.05 vs. Laser + rGO; §p < 0.005 vs. Laser + rGO/MTX). (C) Survival rates of rechallenged mice, after successfully
treatment by rGO/MTX/SB based PTT. (n = 5). 4T1 tumor-bearing mice ‘cured’ by rGO/MTX/SB based PTT were rechallenged with 2 × 10⁵ viable
4T1 or CT26 tumor cells 100 days after the initial challenge. Naïvemice of the same age were used as controls. Reprinted with permission from
reference [157]. Figure obtained from https://doi.org/10.1016/j.biomaterials.2020.120421.
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Table : Nano-ablative immunotherapy strategies for cancer treatment highlighted in this review paper.









Clearance of cutaneous recurrences months after treatment.
Clearance of lung metastases  months after treatment. Pa-





IIa or below), human
PTT
 ±  nm
.–. W
 min
/ patients: tumor-free in ablation zone within  months
/ patients: tumor-free in ablation zonewithinmonths.
Little to no side effects reported due to nanoparticles.
[]




Significant delay of primary and metastatic tumor growth.








Inhibition of tumor growth and prevention of lung metastasis.
Improvement of survival rate.
[]




Survival rate: %. Combination with anti-CTLA- ICT:
achievement of long-term survival in % of mice & devel-
opment of tumor-specific immunity in % of mice. T
rechallenge on surviving mice: complete rejection of tumor
growth was only observed in some UCNP/ICG/
RB-mal + PTT + anti-CTLA- ICT receiving mice.
[]




Complete elimination of tumor after  days in intratumorally
injected group and  days in intravenously injected group. No
observed recurrence after  days.
[]






Elimination of primary tumor and prevention of metastases to
lungs/liver. Control (but not elimination) of untreated tumor
growth for up to  days.
[]




Control of CT tumor growth. Prolongation of survival in
approximately % of animals.
[]




Inhibition of lung metastasis and extension of survival time.
Combination with anti-CTLA-: enhancement of efficacy
leading to long-term survival of approximately %of treated
animals.
[]






Complete eradication of tumor. Inhibition of tumor recurrence
and metastasis.
[]
PLGA-R@Cat + RT CT, BALB/c RT
X-ray dose:
 Gy
Reduction and/or elimination of tumor growth. Prevention of
tumor growth after rechallenge. Combination with anti-
CTLA-: % long-term survival after treatment.
[]




Long-term survival rate: %. Rechallenge: rejection of tumor
growth in % of animals.  days after treatment: control
(but not elimination) of untreated tumor growth.
[]
APNA, activated polymeric nanoagonist; APANP, anti-PD- peptide; Cat, catalase; CCM, cancer cell membrane; CP, compound polysaccharide;
CT, murine colorectal carcinoma; GC, glycated chitosan; Hela, human cervix epithelioid carcinoma; ICG, indocyanine green; Met, metformin;
MDA-MB-: human breast adenocarcinoma; MTX, mitoxantrone; OVA, ovalbumin; PEG, poly(ethylene-glycol); PLGA, poly(lactic-co-glycolic)
acid; PTT, photothermal therapy; RB, rose bengal; RT, radiotherapy; rGO, reduced graphene oxide; SB, SB-; T, murine mammary
carcinoma; SP, superparticle; SWNT, single-walled carbon nanotube; UCNP, upconversion nanoparticle.
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5 Impact of TME on cancer
treatment
The TME is a complex ecosystem consisting of many
different types of cells that influence immune cell activation
and responses to cancer therapeutics (Figure 2). The goal of
NAIT is to alter the TME to promote immune-mediated
killing of the treated tumor and untreated metastases. From
the experimental models described above, NAIT combined
with ICT was often not enough to treat certain tumors, and/
or generate effective immune memory that targets metas-
tases. Most of the studies highlighted in this review used
“cold” tumor models with little immune infiltration, which
explains why ICT does not have considerable abscopal af-
fects following NAIT. To circumvent this limitation, the type
of TME the tumor establishes needs to be considered
(Figure 2). Based on responses to ICT, the TME can generally
be divided into four different types (Figure 7), based on tu-
mor mutational burden (TMB) and inflammatory gene sig-
natures (IGS) [14]. Type 1 tumors have a high TMB and IGS,
making these tumors the prime responders to ICT. Type 2
tumors have a low TMB and IGS. Several factors contribute
to this, including lack of chemokine production to recruit
immune cells into the tumor, and/or the production of
immunosuppressive cytokines to prevent immune activa-
tion via TAMs, MDSC, CAFs, and/or tumor cells. Small
molecules specifically inhibiting the immunosuppressive
cytokines or immunosuppressive cells residing within these
TMEs should be combined with NAIT to improve the
abscopal effect of tumor infiltrating T and NK cells. Other
factors, not fully appreciated, are high IFP and the rigidity of
the solid tumor, which are known barriers, preventing
diffusion of chemotherapeutic drug and nanoparticles [164,
165]. These physical barriers are also likelypreventing tumor
immune cell infiltration and limiting the abscopal effect of
NAIT. For this reason, using a combination of ablative ap-
proaches and nanomedicine may be necessary.
Type 3 tumors exhibit a high TMB but lack a sub-
stantial IGS. This TME is characterized by the expression
of immunosuppressive metabolites, cytokines, and im-
mune modulating molecules like PD-L1. Furthermore,
chemokines that recruit inflammatory cells are reduced in
expression, preventing the intratumoral recruitment of
tumoricidal T cells. ICD of the tumor cells will initiate the
production of chemokines that recruit proinflammatory
immune cells [166, 167]. However, if the immunosup-
pressive cells, cytokines, and/or metabolites are not
altered, the infiltrating tumoricidal cells will have limited
effect. For these types of tumors, NAIT should be com-
bined with NPs containing chemotherapeutic drugs and
immunosuppressive metabolite inhibitors to enhance
abscopal effects. The idea being that the multifunctional
NP delivers the chemotherapy drug(s) that initiate tumor
ICD, while simultaneously blocking the functions of the
immunosuppressive metabolites, resulting in satisfactory
immune infiltration, stimulation, and tumor killing. Thus,
chemotherapies combined with metabolite modulators
that inhibit IDO, arginase I, ROS, etc., or inhibitory cyto-
kines (Figure 2) will help transform the TME to make it
more amenable for tumoricidal activity and enhance
the abscopal effect of NAIT. Another factor that may
contribute to the lack of ISG is IFP and rigidity of
the tumor as mentioned for type 2 TMEs. To circumvent
these barriers, combination ablative approaches may be
required to enhance abscopal affects.
Type 4 tumors present a low TMB but a high IGS. Im-
mune escape is primarily contributed to the infiltration of
immunosuppressive TAMs, MDSCs, and Tregs. These cells
produce copious amounts of immune inhibiting molecules
but can also directly interact with tumoricidal NK and T cells
to prevent tumor killing. Additionally, the high production
of anti-inflammatory chemokines prevents the recruitment
of antitumor immune cells. Combining chemotherapeutic
drugs with cytokine and MDSC/TAM/Treg inhibitors with
NAIT may lead to greater abscopal effects and potential
long-term control of secondary tumors. The rationale is as
follows. In the untreated metastasis, the NP can deliver the
chemotherapeutic drug(s) to initiate ICD. When combined
with anti-inflammatory cytokine blockers or MDSC/TAM/
Treg inhibitors that either block their recruitment and/or
function, proinflammatory immune cells can infiltrate the
tumor and maintain their tumor killing functions. Another
factor to consider when dealingwith any of the four types of
TMEs listed above is that the TME is constantly evolving and
selecting more “fit” tumor cells, capable of resisting cancer
therapy. Additionally, the metastatic tumors can have
different TMEs compared to the primary tumor and/or NAIT
treated tumors. Thus, several doses of multimodal NPs will
likely be required for a curative effect, and/or the treatments
will likely evolve along with the tumors to maintain thera-
peutic efficacy.
6 Further considerations and
conclusions
Over the past several decades, considerable advances have
been made in nano-, photo-, and immuno-mediated ther-
apies. Separately, these technologies have provided diag-
nostic and therapeutic tools for many different diseases.
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However, NAIT synergizes all three to provide a cancer
therapeutic approach capable of overcoming the complex
TME and promoting tumor regression. Great progress
has been made in this area of research, leading to novel
combination therapies that enhance current immunother-
apies such as ICT. As discussed above, PTT combined with
immune stimulation allows for ICT-resistant tumors to
respond to ICT and undergo regression in both preclinical
and clinical studies. However, as the above studies also
revealed, stimulating the immune system alone is not
enough to overcome highly immunosuppressive TMEs of
nontreated metastases. For this reason, combining im-
mune stimulation with TME modulators may be required
for activated immune cells to enter the highly immuno-
suppressive TMEs andmaintain their tumor killing activity.
Chen and colleagues combined PTT with rGO that initiates
proinflammatory cytokine production (IL-1β, IL-6, and
TNFα), a TGFβ inhibitor, and a chemotherapeutic drug
MTX to initiate immune mediated tumor killing [157]. This
worked well on small immunologically “cold” 4T1 tumors,
but it had limited abscopal effects on untreated distant
tumors. This is largely due to the TME, which is a major
Figure 7: The tumor microenvironment can be divided into four groups based on tumor mutational burden (TMB) and inflammatory gene
signatures (IGS) such as type II IFN response genes. (A) Type 1 tumorswith a high TMBand IGSandhigh T cell infiltration. (B) Type2 tumorswith
a low TMBand IGS, and low T cell infiltration. (C) Type 3 tumorswith a high TMBbut a low IGS and low T cell infiltration. (D) Type 4 tumorswith a
low TMB but a high IGS and high T cell infiltration.
3260 A.R. Hoover et al.: Nano-ablative immunotherapy for cancer
factor limiting successful cancer therapy, especially on
cancers that cannot be treated with PTT to disrupt tumor
homeostasis in order to enhance tumor killing. The type of
TMEs impacts the efficacy of ICT and other immunother-
apies. Different approaches could be combined to possibly
overcome these limitations.
NAIT provides a powerful approach to deliver combi-
natorial therapeutics to treat cancer through multiple
pathways. The personalization of NAIT makes it incredibly
durable in unleashing the full potential of antitumor im-
munity, not only to eliminate the treated primary tumor, but
also to eliminate distantmetastases. Futurework combining
TME modulators with NAIT offers a bright future for cancer
treatment, particularly for eliminating distant metastases
with unique TME immune signatures and stimulating
effective antitumor memory.
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